TITLE

Pharmacological Considerations in Human Immunodeficiency Virus-Infected Adults in the Intensive Care Unit

AUTHOR(S)
Defreitas, Ashley A.; D┬┐souza, Theresa-Lynda M.; Lazaro, Ginille J.; Windes, Emily M.; Johnson, Melissa D.; Relf, Michael V.
PUB. DATE
April 2013
SOURCE
Critical Care Nurse;Apr2013, Vol. 33 Issue 2, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
According to estimates, 1.2 million Americans are infected with human immunodeficiency virus (HIV). Because of antiretroviral therapy, persons who have HIV infection or have progressed to AIDS are living longer. As a result, the likelihood that they will need critical care nursing is increasing. Unlike in years past, when these patients were often admitted because of the consequences of immunosuppression, today they are also being cared for in critical care units for other conditions associated with aging, other chronic health conditions, and trauma. When persons who have HIV disease or AIDS are admitted to the intensive care unit, nurses must be prepared to provide care, especially management of complexities associated with antiretroviral therapy. Therefore, this article examines critical care nurses' role in initiating and administering antiretroviral therapy in the intensive care unit and reducing the risk of drug interactions associated with the therapy.
ACCESSION #
86413740

 

Related Articles

  • Dispassionate assessment. Croser, D. // British Dental Journal;2/24/2007, Vol. 202 Issue 4, p176 

    A letter to the editor about the United Kingdom Advisory Panel's assessment of the risk posed by a human immunodeficiency virus infected dentist is presented.

  • Antibacterials/valproate semisodium.  // Reactions Weekly;Mar2014, Vol. 1494 Issue 1, p9 

    An abstract of the article "Vanishing bile duct syndrome in human immunodeficiency virus infected adults: A report of two cases," by A. P. Oppenheimer and colleagues, is presented.

  • Gap in HIV infection widens. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);07/04/98, Vol. 317 Issue 7150, p11 

    Reports on the rate of human immunodeficiency virus infection (HIV) worldwide, according to an analysis by the United Nations programme on HIV/AIDS. Statistical information on the prevalence of HIV infection in adults in 1997; Factors influencing the spread of HIV infection; Percentage of...

  • Biological Considerations in the Development of a Human Immunodeficiency Virus Vaccine. Nathanson, Neal; Mathieson, Bonnie J. // Journal of Infectious Diseases;8/1/2000, Vol. 182 Issue 2 

    Evaluates the biological considerations in the development of a human immunodeficiency virus vaccines. Failure of the recombinant envelop proteins for eliciting cellular immune reponse; Retention of the pathogenicity of the similar immunodeficiency virus strain; Immunization against virus...

  • Effect of HIV Infection and Tuberculosis on Hospitalizations and Cost of Care for Young Adults in the United States, 1985 to 1990. Rosenblum, Lisa S.; Castro, Kenneth G.; Dooley, Samuel; Morgan, Meade // Annals of Internal Medicine;11/15/94, Vol. 121 Issue 10, p786 

    Provides information on a study that evaluated the effect of human immunodeficiency virus infection and tuberculosis on hospitalizations and the cost of care. Methodology of the study; Results and discussion on the study.

  • Antiretroviral Approved for Use in Infants. Preboth, Monica // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2469 

    Reports on the approval of lopinavir-ritonavir for the treatment of human immunodeficiency virus infection in adults and children six months and older in combination with other antiretroviral medications by the United States Food and Drug Administration. How the drug is administered; Side effects.

  • Time for AIDS leadership, at home and in Africa. Bond, Julian // New York Amsterdam News;12/23/99, Vol. 90 Issue 52, p13 

    Calls for a collective action from African-American politicians in the United States and Africa against the Acquired Immune Deficiency Syndrome disease. Emphasis on preventing human immunodeficiency virus infections; Susceptibility of African-Americans to having the disease; Percentage of human...

  • What is the issue?: Pseudoaddiction or undertreatment of pain. Kowal, Nancy // Nursing Economic$;Nov/Dec99, Vol. 17 Issue 6, p348 

    Focuses on substance abuse disorder in the United States and its impact on assessment and management parameters in health care. Association of drug abuse with diseases such as cancer, liver disease and human immunodeficiency virus infection; Substance abuse disorders in the clinically ill.

  • UN Secretary-General Ban Ki-moon appoints Speciosa Wandira-Kasibwe of Uganda as his Special Envoy for HIV/AIDS in Africa.  // African Business News;8/ 1/2013, p42 

    The article announces that the United Nations Secretary-General has appointed Speciosa Wandira-Kasibwe as his Special Envoy for human immunodeficiency virus infection /acquired immunodeficiency syndrome (HIV/AIDS) in Africa.

  • Randomized Controlled Trial of Mycobacterium vaccae Immunotherapy in Non-Human Immunodeficiency Virus-Infected Ugandan Adults with Newly Diagnosed Pulmonary Tuberculosis. Johnson, John L.; Kamya, R. Moses; Okwera, Alphonse; Loughlin, Anita M.; Nyole, Sam; Hom, David L.; Wallis, Robert S.; Hirsch, Christina S.; Wolski, Kathy; Foulds, John; Mugerwa, Roy D.; Ellner, Jerrold J. // Journal of Infectious Diseases;4/1/2000, Vol. 181 Issue 4 

    Examines the immunologic effects of mycobacterium vaccae immunotherapy on non-human immunodeficiency virus-infected adults with pulmonary tuberculosis in Uganda. Pathogenesis of mycobacterium vaccae; Effectiveness of randomized placebo-controlled trial in evaluating the effects.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics